Targeting ret-driven cancers: Lessons from evolving preclinical and clinical landscapes

Keyphrases

• Targeted Therapy 100%
• Solid Tumors 66%
• Multikinase Inhibitor 66%
• Tumor 33%
• Oncogenic Drivers 33%
• Response Rate 33%
• Specific Inhibitor 33%
• Clinical Efficacy 33%
• Oncogenesis 33%
• Drug Target 33%
• Lung Cancer 33%
• BRAF V600E mutation 33%
• Oncoprotein 33%
• Thyroid Cancer 33%
• Targeted Therapeutics 33%
• Direct Therapy 33%
• Regulatory Approval 33%
• Tractability 33%
• RET mutation 33%
• Multikinase Inhibition 33%
• Receptor Tyrosine Kinase RET 33%
• ROS1 Rearrangement 33%
• RET Rearrangement 33%
• ALK Rearrangement 33%
• Sensitising EGFR mutation 33%

Medicine and Dentistry

• Cancer 100%
• Targeted Therapy 100%
• Carcinogenesis 66%
• Solid Malignant Neoplasm 66%
• Lung Cancer 33%
• Protein Tyrosine Kinase 33%
• Tumor 33%
• Epidermal Growth Factor Receptor 33%
• Thyroid Cancer 33%
• Oncoprotein 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Carcinogenesis 100%
• Solid Malignant Neoplasm 100%
• Protein Tyrosine Kinase 50%
• Epidermal Growth Factor Receptor 50%
• Lung Cancer 50%
• Thyroid Cancer 50%
• Oncoprotein 50%